Literature DB >> 22594955

Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses.

T W McGowan1, G P Pinchbeck, C M McGowan.   

Abstract

REASONS FOR PERFORMING STUDY: Equine pituitary pars intermedia dysfunction (PPID) is an ageing-related neurodegenerative disorder. The prevalence and risk factors for PPID using seasonally adjusted basal adrenocorticotropic hormone (ACTH) concentrations in aged horses have not been previously reported.
OBJECTIVES: To determine the prevalence, risk factors and clinical signs predictive for PPID in a population of horses aged ≥ 15 years in Queensland, Australia.
METHODS: Owner-reported data was obtained using a postal questionnaire distributed to an equestrian group. A subgroup of surveyed owners were visited and a veterinary physical examination performed on all horses aged ≥ 15 years. Blood samples were analysed for basal plasma alpha melanocyte-stimulating hormone (α-MSH) and ACTH concentrations, routine haematology and selected biochemistry. Aged horses with elevations above seasonally adjusted cut-off values for basal plasma ACTH were considered positive for PPID. Positive horses were compared with their aged counterparts to determine risk factors and clinical signs associated with PPID.
RESULTS: Pituitary pars intermedia dysfunction was prevalent in aged horses (21.2%) despite owners infrequently reporting it as a known or diagnosed disease or disorder. Numerous clinical or historical signs were associated with an increased risk of PPID in the univariable model, but only age (odds ratio (OR) 1.18; 95% confidence interval (CI) 1.11-1.25, P<0.001) and owner-reported history of hirsutism (OR 7.80; 95% CI 3.67-16.57, P<0.001) remained in the final multivariable model. There were no routine haematological or biochemical variables supportive of a diagnosis of PPID. CONCLUSIONS AND POTENTIAL RELEVANCE: Pituitary pars intermedia dysfunction occurs commonly in aged horses despite under-recognition by owners. The increased risk of PPID with age supports that this is an ageing associated condition. Aged horses with clinical or historical signs consistent with PPID, especially owner-reported hirsutism (delayed shedding and/or long hair coat), should be tested and appropriate treatment instituted.
© 2012 EVJ Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22594955     DOI: 10.1111/j.2042-3306.2012.00578.x

Source DB:  PubMed          Journal:  Equine Vet J        ISSN: 0425-1644            Impact factor:   2.888


  25 in total

1.  Equine pituitary pars intermedia dysfunction: An international survey of veterinarians' approach to diagnosis, management, and estimated prevalence.

Authors:  James L Carmalt; Cheryl L Waldner; Andrew L Allen
Journal:  Can J Vet Res       Date:  2017-10       Impact factor: 1.310

2.  Comparison of two methods for measurement of equine adrenocorticotropin.

Authors:  Heidi E Banse; Nichol Schultz; Molly McCue; Ray Geor; Dianne McFarlane
Journal:  J Vet Diagn Invest       Date:  2017-12-28       Impact factor: 1.279

3.  Effect of Age, Season, Body Condition, and Endocrine Status on Serum Free Cortisol Fraction and Insulin Concentration in Horses.

Authors:  K A Hart; D M Wochele; N A Norton; D McFarlane; A A Wooldridge; N Frank
Journal:  J Vet Intern Med       Date:  2016-02-09       Impact factor: 3.333

4.  Profiles of pro-opiomelanocortin and encoded peptides, and their processing enzymes in equine pituitary pars intermedia dysfunction.

Authors:  James L Carmalt; Sima Mortazavi; Rebecca C McOnie; Andrew L Allen; Suraj Unniappan
Journal:  PLoS One       Date:  2018-01-08       Impact factor: 3.240

5.  The Effect of Geographic Location on Circannual Adrenocorticotropic Hormone Plasma Concentrations in Horses in Australia.

Authors:  C J Secombe; R H H Tan; D I Perara; D P Byrne; S P Watts; J G Wearn
Journal:  J Vet Intern Med       Date:  2017-06-29       Impact factor: 3.333

6.  The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies.

Authors:  Alexandra Meier; Dania Reiche; Melody de Laat; Christopher Pollitt; Donald Walsh; Martin Sillence
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

7.  Clinical and Pathological Features of Pheochromocytoma in the Horse: A Multi-Center Retrospective Study of 37 Cases (2007-2014).

Authors:  D Luethy; P Habecker; B Murphy; R Nolen-Walston
Journal:  J Vet Intern Med       Date:  2015-11-27       Impact factor: 3.333

Review 8.  Equine pituitary pars intermedia dysfunction: current perspectives on diagnosis and management.

Authors:  Caroline W Spelta
Journal:  Vet Med (Auckl)       Date:  2015-08-20

9.  Use of principle component analysis to quantitatively score the equine metabolic syndrome phenotype in an Arabian horse population.

Authors:  Samantha L Lewis; Heather M Holl; Maureen T Long; Martha F Mallicote; Samantha A Brooks
Journal:  PLoS One       Date:  2018-07-12       Impact factor: 3.240

10.  Dysregulation of Cortisol Metabolism in Equine Pituitary Pars Intermedia Dysfunction.

Authors:  Ruth A Morgan; John A Keen; Natalie Homer; Mark Nixon; Anna M McKinnon-Garvin; Jodie A Moses-Williams; Sarah R Davis; Patrick W F Hadoke; Brian R Walker
Journal:  Endocrinology       Date:  2018-11-01       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.